Bank of America Spends $250M Annually on Employee GLP-1 Coverage

What happened

CEO Brian Moynihan disclosed that Bank of America now spends over $250 million annually on GLP-1 medications such as Ozempic, Wegovy, and Zepbound for its approximately 211,000 employees. This expenditure has grown from zero just four or five years ago and now accounts for roughly 13% of the company's $2 billion total healthcare budget. The bank has chosen to maintain and expand coverage rather than restrict access, pairing medication benefits with health coaching programs focused on weight management, nutrition, and lifestyle changes. Moynihan reported that the company is already observing measurable results in employee weight loss and health improvements. The medications, which can cost thousands of dollars per patient annually, have driven healthcare spending increases of approximately 15 percent in recent quarters. Bank of America has implemented oversight measures including prior authorization requirements and step therapy protocols while continuing to cover the drugs for employees meeting clinical criteria.

Why it matters

The disclosure highlights how rapidly GLP-1 medications have become a significant line item in corporate healthcare budgets and illustrates divergent employer strategies in managing these costs. While 36% of employers now cover GLP-1s for both diabetes and weight loss according to a 2026 survey, many organizations including PwC have eliminated weight loss coverage due to expense concerns. Bank of America's approach represents a calculated investment in workforce health, with Moynihan emphasizing emerging research linking these drugs to lower rates of cardiovascular events and obesity-related complications that could reduce future healthcare costs. The bank's experience demonstrates the tension employers face between providing valuable health benefits that support productivity and retention versus managing substantial cost pressures. For the GLP-1 sector, employer coverage remains a critical pathway for adoption, with drugmakers like Eli Lilly introducing employer-focused programs such as a multi-dose Zepbound version at $449 per month to encourage corporate uptake.

Bigger picture

Bank of America's spending reflects broader industry trends affecting major employers as GLP-1 utilization accelerates nationwide. According to the International Foundation of Employee Benefit Plans survey, these medications accounted for 11.4% of employers' annual healthcare claims in 2026, up sharply from 6.9% three years earlier. The rapid cost escalation has created a significant financial challenge across corporate America, with analysts estimating that GLP-1 drugs could add billions of dollars in annual costs to the U.S. healthcare system at current adoption rates. Expanded clinical recommendations from the American Diabetes Association and American Heart Association beyond diabetes management to include cardiovascular risk reduction and obesity treatment have encouraged broader prescribing patterns. Direct-to-consumer advertising and widespread media coverage have further heightened employee demand. The sector faces ongoing pricing debates, with advocacy groups and lawmakers questioning manufacturer list prices while companies like Novo Nordisk and Eli Lilly defend costs based on extensive research investments and large-scale clinical trials demonstrating cardiovascular benefits.

What to watch

Monitor whether Bank of America's long-term bet on employee health yields measurable returns through reduced downstream healthcare costs in cardiovascular events, hospital visits, and chronic disease management. Track employer adoption patterns as more real-world data accumulates on patient adherence rates, since discontinuation due to side effects or weight regain could undermine projected savings. Watch for pricing developments as oral GLP-1 formulations in late-stage trials reach market, potentially improving convenience and expanding patient populations. Observe whether manufacturers successfully expand label indications to heart failure, chronic kidney disease, and neurodegenerative conditions, which would increase both medical value and employer budget impacts. Follow ongoing negotiations between large employers and pharmacy benefit managers as companies seek better rebates and more sustainable pricing models.